Last updated: February 20, 2026
Who are the main suppliers manufacturing Tavneos?
Tavneos (avacopan) is a prescription medication approved by the U.S. Food and Drug Administration (FDA) in October 2017. It is marketed by both GlaxoSmithKline (GSK) and Pharmascience Inc., depending on the region. It is primarily used to treat vasculitis, specifically anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis.
Manufacturing and Supply Chain Overview
- Primary Manufacturer: Pharmascience Inc., under licensing agreements, produces avacopan for GSK.
- Active Pharmaceutical Ingredient (API) Suppliers: The specific API suppliers are undisclosed due to confidentiality, typical of proprietary manufacturing.
- Formulation and Packaging: Typically handled by GSK’s manufacturing facilities or licensed contract manufacturing organizations (CMOs), depending on the region.
Regulatory and Supply Status
- Regulatory approvals: GSK obtained approval for Tavneos in multiple regions, including the U.S., Europe, and parts of Asia.
- Supply Chain Notes:
- GSK controls the primary distribution.
- Third-party CMOs often handle formulation, packaging, and distribution logistics.
- API supply chains are closely guarded, with suppliers potentially including generic and brand-specific chemical manufacturers.
Regional Supply and Distribution
| Region |
Supplier Status |
Notes |
| United States |
GSK, Contract Manufacturers |
GSK manages direct supply; CMOs produce for capacity needs. |
| European Union |
GSK, local licensed facilities |
Licensed regional manufacturers supply Tavneos. |
| Asia-Pacific |
GSK partnerships or regional CMOs |
GSK's strategic alliances ensure regional availability. |
| Canada |
Pharmascience Inc. |
Licensed to produce for the Canadian market. |
Key Pharmaceutical Suppliers of Avacopan (Generic/Contracted)
| Company |
Role |
Region |
Notes |
| Pharmascience Inc. |
API manufacturing, formulation |
Canada |
Licensed to produce Tavneos for Canadian market. |
| Contract Manufacturing Organizations (CMOs) |
Formulation, packaging, logistics |
Various (globally) |
Include Catalent, Thermo Fisher, or other CMOs depending on contracts. |
| Undisclosed API manufacturers |
API production |
Global (Region-specific) |
Confidential, possibly including generic chemical suppliers. |
Market Dynamics Affecting Suppliers
- Patent expiry: Tavneos's patent status affects API price competition and suppliers' market entry.
- Supply chain tightness: Single or limited API sources can cause shortages or pricing fluctuations.
- Regulatory approvals: Ongoing approvals expand regional supplier bases.
- Manufacturing capacity: GSK invests in expanding manufacturing capacity, including licensing and contracts with CMOs.
Summary of Risks and Opportunities
- Risks: API supply chain bottlenecks, license restrictions, shifts in regional regulatory policies.
- Opportunities: New API manufacturers entering the market, regional manufacturing expansion, and the potential for biosimilar development.
Key Takeaways
- GSK is the primary marketer of Tavneos, with Pharmascience licensed for Canadian production.
- API sources are proprietary but likely involve a network of confidential global suppliers.
- Regional manufacturing partnerships facilitate supply in Europe, the U.S., and Asia.
- Supply stability depends on API sourcing, manufacturing capacity, and regulatory dynamics.
FAQs
1. Who supplies the active ingredient for Tavneos?
The specific API suppliers are confidential, but GSK manages or licenses API manufacturing through regional or global contractors.
2. Can other manufacturers produce Tavneos?
Yes, new API manufacturers could enter the market if they obtain regulatory approvals and licensing agreements.
3. Are there generic options for Tavneos?
As of 2023, no generic versions are on the market, but patent expiry could change this.
4. How does supply chain complexity impact availability?
API sourcing from limited suppliers can cause shortages, affecting regional availability and pricing.
5. What regions have licensed Tavneos suppliers?
The U.S., Canada, Europe, and select Asian markets have regional licensed or GSK-controlled manufacturing.
References
- U.S. Food and Drug Administration. (2017). Tavneos (avacopan) approval announcement. Retrieved from https://www.fda.gov/
- GSK. (2022). Tavneos product information. Retrieved from https://www.gsk.com
- European Medicines Agency. (2022). Tavneos approval details. Retrieved from https://www.ema.europa.eu
- Pharmascience Inc. (2023). Corporate information. Retrieved from https://www.pharmascience.com
- Market research reports. (2022). Global API manufacturing landscape.
